- Open Access
Novelty in hypertension in children and adolescents: focus on hypertension during the first year of life, use and interpretation of ambulatory blood pressure monitoring, role of physical activity in prevention and treatment, simple carbohydrates and uric acid as risk factors
- Mirella Strambi1, 2,
- Marco Giussani1, 3Email author,
- Maria Amalia Ambruzzi1,
- Paolo Brambilla4,
- Ciro Corrado1, 5,
- Ugo Giordano1, 6,
- Claudio Maffeis7,
- Silvio Maringhin1, 5, 8,
- Maria Chiara Matteucci1, 9,
- Ettore Menghetti1,
- Patrizia Salice1, 10, 11,
- Federico Schena12,
- Pietro Strisciuglio1, 13,
- Giuliana Valerio14,
- Francesca Viazzi15,
- Raffaele Virdis1, 16 and
- Simonetta Genovesi17, 18, 19
© The Author(s). 2016
- Received: 19 March 2016
- Accepted: 5 July 2016
- Published: 16 July 2016
The present article intends to provide an update of the article “Focus on prevention, diagnosis and treatment of hypertension in children and adolescents” published in 2013 (Spagnolo et al., Ital J Pediatr 39:20, 2013) in this journal. This revision is justified by the fact that during the last years there have been several new scientific contributions to the problem of hypertension in pediatric age and during adolescence. Nevertheless, for what regards some aspects of the previous article, the newly acquired information did not require substantial changes to what was already published, both from a cultural and from a clinical point of view. We felt, however, the necessity to rewrite and/or to extend other parts in the light of the most recent scientific publications. More specifically, we updated and extended the chapters on the diagnosis and management of hypertension in newborns and unweaned babies, on the use and interpretation of ambulatory blood pressure monitoring, and on the usefulness of and indications for physical activity. Furthermore, we added an entirely new section on the role that simple carbohydrates (fructose in particular) and uric acid may play in the pathogenesis of hypertension in pediatric age.
- Physical Activity
- Uric Acid
- Sedentary Behavior
- Pulse Wave Velocity
- Uric Acid Level
A few years ago we published in this journal an article on prevention, diagnosis and treatment of hypertension in children. During the last years there have been several new scientific contributions to the problem of hypertension in pediatric age and during adolescence. For this reason we felt the necessity to rewrite and/or to extend some parts of the previous article in the light of the most recent scientific publications.
Hypertension in newborns and unweaned babies
Gestational age and blood pressure values in newborns
The method used for measuring blood pressure is an important factor. In newborns, when invasive recording of blood pressure is impossible, the oscillometric method is almost universally accepted as being reliable. The majority of measuring errors is caused by the use of inappropriate cuffs, a mistake that occurs in older children as well. Whereas in children it is advised that the width of the cuff be 40 % of the circumference of the arm, in newborn babies it has been shown that by using a cuff whose width equals 50 % of the arm circumference it is possible to detect blood pressure values that correspond with the intra-arterial ones . It has also been demonstrated that the choice of the cuff after actual measurement of the arm’s circumference is much more accurate than the choice based on visual assessment, even if done by expert health workers . Therefore the measurement of the arm circumference is an essential aspect of blood pressure assessment in neonates.
We can conclude that blood pressure measurement shouldn’t routinely be done in healthy newborns, but we also think that is mandatory to monitor blood pressure in neonatal intensive care unit, particularly in subjects submitted to mechanical ventilation, in sub-intensive care and whenever a newborn is at high risk for hypertension, due to either sickness or syndromic clues. The potential harms caused by false diagnosis of hypertension must be kept in mind and avoided by repeated measurements, performed by expert health workers.
Causes of hypertension in neonates
Causes of neonatal hypertension
Renal artery stenosis
Renal artery thrombosis
Renal venous thrombosis
Renal parenchymal disease/obstructive uropathy
Polycystic kidney disease
Acute tubular necrosis
Severe vesicoureteral reflux
Stenosis of ureteropelvic junction
Posterior urethral valve
Other causes of acute and chronic renal insufficiency
Aortic arch reconstruction
Patent ductus arteriosus
Congenital adrenal hyperplasia (17 alpha or 11 beta hydroxylase deficiency)
Abstinence syndrome from opioid withdrawal
Closure of abdominal wall defect
Dexamethasone and other corticosteroids
Methylxanthines (caffeine, theophylline)
Vasoactive amines (dopamine, adrenaline)
Parenteral nutrition (volume overload, sodium, calcium)
Extracorporeal respiratory assistance
Guiding criteria for the diagnosis of neonatal hypertension
The most frequent prenatal causes of neonatal hypertension are:
1. repeated use of steroids by mother
2. maternal diabetes mellitus
3. maternal hypertension
The most frequent postnatal causes of neonatal hypertensione are:
1. thromboembolism associated with the placement of an umbilical cathether, involving an acute risk presumably due to endothelial damage and a chronic risk related to the time the cathether stays in place
2. renal parenchymal disease, both congenital (eg. polycystic kidney disease) and acquired
3. bronchopulmonary dysplasia (CLD)
The presence of thrombophilia may confirm the hypothesis of renal vein thrombosis. Only as a second step and if the clinical history suggests to do so, cortisol and aldosterone levels and the thyroid function should be assessed. Plasma renin activity is normally very high in newborns, and consequently it is not to be assessed, unless a marked hypokalemia is found that may possibly be related to a genetic anomaly in the tubular sodium management. Echo-Doppler examination of the renal vessels is essential for excluding renal malformations and aortic or renal intravascular thrombi. Until a few years ago, angiography was considered the gold standard for the diagnosis of renal artery stenosis due to fibrodysplasia, but was difficult to carry out in newborns. The search for less invasive diagnostic methods has recently resulted in obtaining a very high diagnostic sensitivity and specificity by combining color-Doppler technique to nuclear magnetic resonance or to a computed tomography scan with contrast. This latter method provides better definition, even though at a high level of toxicity [24, 25].
Drugs useful in the treatment of neonatal hypertension
Rapid bolus injection
Slow injection is ineffective.
May cause rapid hypotension.
15 ± 5 μg/kg/dose; repeat after 8–24 h
Injection over 5–10 min
May cause prolonged hypotension and acute renal insufficiency.
Very short-acting. Constant infusion necessary.
Bolus: 0.15–0.6 mg/kg/dose every 4 h.
Drip: 0.75–5.0 μg/kg/min
IV bolus or infusion
Frequently causes tachycardia.
α- and β-blocker
IV bolus or constant infusion
Heart failure and BPD are relative contraindications.
May cause reflex tachycardia.
Vasodilator (arteriolar and venous)
In case of prolonged therapy (>72 h) or renal failure thiocyanate toxicity may occur.
Monitor serum creatinine and potassium.
Side effects: sedation, dryness of the mucosa. Abrupt interruption may cause rebound hypertension.
0.25–1.0 mg/kg (max 7.5 mg/kg per day)
Frequent side effects: fluid retention and tachycardia. Lupus-like syndrome may occur in slow acetylators.
Useful for both chronic and acute hypertension.
Causes sudden hypertension less frequently than isradipine.
Max. dose: 1–2 mg/kg per day
Repeat every 4–6 h
Hypotensive response poorly predictable.
The most potent oral vasodilator. Hypertrichosis in case of prolonged use.
Maximum dose to be defined according to heart rate (up to 8–10 mg/kg if no bradycardia). Not to be used in infants with BPD.
Max. dose 2 mg/kg per day
α- and β-blocker
Monitor heart rate. Not to be used in infants with BPD.
Potassium-sparing. Check serum electrolytes. May take several days to reach maximum effectiveness.
Check serum electrolytes.
Check serum electrolytes.
Hypertension is the main cause of myocardial hypertrophy with consequent fibrosis and dilatation; in adults such conditions are associated with cardiac and non-cardiac morbidity and untimely mortality [31–33] Antihypertensive therapy causes a reduction in blood pressure and cardiac mass. However, it has never been demonstrated that normalization of blood pressure and cardiac mass brings cardiovascular risk to the same level of subjects who were never hypertensive; what is more, it seems that hypertensive patients, even though treated correctly and achieving efficient reduction of blood pressure levels, still remain at increased risk compared to normotensives. The few available studies on this subject in pediatric age seem to support this theory [34, 35]. Thus it is important, even in young children, to prevent hypertension or at least prevent left ventricular hypertrophy. Cardiac hypertrophy can be easily assessed by echocardiography that, by measuring the wall thicknesses and dimension of the chambers, allows to determine cardiac mass with an appropriate formula which provides a good correspondence with necropsy left ventricular mass . Cardiac mass as expressed in grams is indexed according to weight and/or height of the subject. Scientific knowledge on hypertension-induced organ damage in childhood is scarce, but it is known that also children react to increases in blood pressure with increases in cardiac mass, and thus presumably suffering all the same consequences and risks as those described for adults . Information on neonates is even more scanty. The heart of newborn infants still has the capacity to increase the number of myocytes (hyperplasia). Within one year of age this capacity gradually diminishes. As the rate of growth of cardiac mass is inversely proportional to age, in a short time lapse severe hypertension can induce a considerable hypertrophy with a consequent rise in the associated risk of death in newborns and unweaned babies . Even if shown in a limited number of subjects, an increase in mass of more than 100 % compared to baseline values may be associated with an increased mortality . In conclusion, a rapid development of ventricular hypertrophy represents a negative prognostic factor of survival and requires a timely and efficient treatment, especially when considering that blood pressure reduction in this age range seems to bring about an correspondingly rapid regression of the hypertrophy. The risks associated to increased cardiac mass and the age-related high rate of hypertrophy development, make careful cardiologic follow-up of cases of severe hypertension in infants and unweaned babies quite crucial. Arterial stiffness evaluated by pulse wave velocity and ultrasonography measurement of intimal media thickness are important independent predictors of cardiovascular events in adults and indicators of cardiovascular risk in childhood [40, 41]. Both pulse wave velocity and intimal media thickness have been shown to be reliably ascertained in newborns with good reproducibility, but normal reference values are still lacking. So it is difficult to distinguish between the normal progressive structural changes in the arterial wall in this age group and differences due to the systemic blood pressure [42, 43]. Furthermore recent data show significantly increased intimal media thickness and pulse wave velocity values during infancy in growth restricted foetuses, not always related to a significant trend because of high blood pressure values, supporting that possibility of fetal cardiovascular programming leading later in life on to hypertension .
Prevention of primary hypertension: programming
In recent years it has been established that primary hypertension, besides being controlled by an important genetic component, is influenced by environmental stimuli according to the concept of programming; i.e. the process by which a stimulus or a lesion to an organism during a critical period of its development determines long-lasting or even permanent effects. While the duration of the stimulus is certainly important, the period in life in which it occurs is even more critical. If common stimuli affecting blood pressure such as stress, diet, drugs, are present during intrauterine life or during the first year of life, they may alter the programming and determine permanent changes in blood pressure . There is some debate about the pathogenetic mechanism; the initial hypothesis that still stands is the so-called unifying pathway by Woods , according to which environmental and placental factors, such as maternal protein restriction, alterations in the placental or uterine circulation, or placental insufficiency, which all determine low birth weight, may cause hypertension in adulthood due to activation of the renin-angiotensin system as a consequence of a low number of nephrons. Furthermore, according to the hypothesis developed by Barker , scarce intrauterine growth would cause a deterioration in insulin resistance, and in turn, elevated levels of insulin have been associated with increased blood pressure also in children . Several studies report that adolescents and adults who were born prematurely have a mean blood pressure that is higher than the one observed in full-term peers or show an increased pressure load (number of ambulatory blood pressure measurements beyond normal values), both indicative of a predisposition for the development of hypertension [49–51]. More recent data suggest that even children of premature parents, though they themselves were born after a full-term delivery, present modest abnormalities in their cardiovascular disposition (higher heart rate or elevated blood pressure values, yet remaining within the normal range). These observations seem to confirm that changes induced by environmental stimuli can be inherited by the following generations . Another important factor is represented by the type of nutrition during the first year of life. One of the beneficial effects of breastfeeding is the reduction of blood pressure at later age, but also mixed feeding seems to be effective. In fact, in 2001 Singhal et al. reported in Lancet  that diastolic blood pressure at 14–16 years of age is inversely proportional to the percentage of mother’s milk in the diet during the first months of life; the more mother’s milk had been consumed, the lower was diastolic blood pressure. It is known that potassium inhibits the renin-angiotensin system. The high content of potassium in vegetables, but also potassium in formula milk, the quantity of which may vary a lot according to the type of milk, may affect blood pressure values [54, 55]. All these studies emphasize the importance of very early preventive strategies, starting as early as in pregnancy, involving lifestyle and diet interventions in order to maintain a healthy condition in the long term.
Ambulatory blood pressure monitoring in pediatric hypertension: how and when to use it
Scheme for the classification of systolic and diastolic blood pressure values obtained by 24-h blood pressure monitoring in children
Office SBP/DBP a
24-h ambulatory SBP/DBP b
SBP or DBP load (%) b
Normal blood pressure
White coat hypertension
Dipping subjects: mean nocturnal values at least 10 % lower than diurnal values
Normal values for ambulatory BP (mmHg) for girls by height
Normal values for ambulatory BP (mmHg) for boys by height
Normal values for ambulatory BP (mmHg) for girls by age
Normal values for ambulatory BP (mmHg) for boys by age
ABPM and organ damage
Several studies reported a correlation between blood pressure values observed in pediatric age and the presence of organ damage in adulthood, and in particular the presence of left ventricular hypertrophy, carotid intima-media thickening and increase in arterial stiffness [62–64]. ABPM appears to be more effective compared to office blood pressure measurements in identifying children at increased risk of developing organ damage. A study by Sorof  clearly shows diagnosis of hypertension in children on the basis of ABPM data is more significantly related to the prevalence of left ventricular hypertrophy than hypertension diagnosed by office blood pressure measurements. In a review of the National High Blood Pressure Education Program Working Group the risk of developing left ventricular hypertrophy, in terms of odds ratio, was 7.2 in hypertension diagnosed by ABPM vs 4.1 in hypertension based on office measurements . In another study, the blood pressure values obtained by ABPM were shown to be superior in predicting LVH than both office and home (self-measurement) blood pressure values . Furthermore, in several studies blood pressure values recorded by ABPM were associated with another well-known cardiovascular risk factor, namely carotid intima-media thickness [68, 69]. Litwin et al.  documented, in 72 children with essential hypertension, a correlation between intima-media thickness in the carotid and superficial femoral arteries and 24-h systolic blood pressure values. Finally, others authors documented a correlation between ABPM values and some parameters of artery distensibility and stiffness or with indices of endothelial dysfunction as flow-mediated or nitroglycerin-mediated dilation [71, 72].
Indications for the use of ABPM
Data provided by ABPM consist of the mean of systolic and diastolic blood pressure values recorded during 24 h and, separately, during waking hours (daytime mean) and during sleep (nighttime mean). The recording of nighttime blood pressure allows the determination of the presence of the physiological fall in blood pressure during sleep (dipping), which should be at least 10 % of the diurnal blood pressure mean. The absence of a nighttime fall in blood pressure and the presence of isolated nocturnal hypertension have been shown to be important prognostic factors in several forms of secondary hypertension, especially those due to renal damage [73–76]. Another important concept to use in the interpretation of a 24-h recording is pressure load. A correct definition of all these parameters requires an adequate identification of the actual periods of sleep and wakefulness in the patient.
ABPM and clinical condition
White coat hypertension
The American recommendations suggest to perform ABPM in children with elevated office blood pressure values in whom an excess reactivity to the measurements (white coat hypertension) is suspected, in order to confirm such possible diagnosis. However, as initial organ damage may already be present in subjects with white coat hypertension [77–80] in the last recommendations it is suggested to consider white coat hypertensives only those subjects with borderline or moderately elevated office blood pressure values, because subjects with even higher blood pressure could be real hypertensives, as demonstrated by Sorof . An increase in left ventricular mass has in fact been demonstrated in children with white coat hypertension  and it has been shown that also subjects who occasionally have blood pressure values above the 95th percentile (transitory hypertensives) may be at increased risk of presenting left ventricular hypertrophy . For these reasons we believe that when normal ABPM values are observed in the presence of elevated office blood pressure values, these children should not be excluded from careful follow-up.
The term prehypertension used in this context should not be confused with the one that was used in the past to define those subjects presenting office blood pressure values above the 90th but below the 95th percentile and that was substituted in the most recent recommendations by the term “high-normal blood pressure”. In the present document prehypertension is defined (Table 5) as high-normal office blood pressure values, 24-h mean ABPM values below the 95th percentile and a blood pressure load of 25 % of the measurements or higher. It should be noted that in the guidelines for adults the concept of diagnosis of prehypertension by ABPM does not exist, as in adults the assessment of pressure load is not used; in children however, this parameter is essential for the definition of prehypertension.
Another important new development in the 2014 recommendations is the introduction of diastolic blood pressure values for the diagnosis of hypertension. In the document of 2008 the diagnosis was based exclusively on systolic blood pressure. The diagnostic use of ABPM-derived diastolic blood pressure values can be important especially in children with secondary hypertension, in whom ABPM may reveal diastolic hypertension , whereas in children with primary hypertension ABPM more frequently indicates systolic hypertension [86, 87].
Technical problems regarding the correct use of Ambulatory Blood Pressure Monitoring in children
Systolic blood pressure
< 60 or > 220 mm Hg
Diastolic blood pressure
< 35 or > 120 mm Hg
< 40 or > 180 beats per minute
< 40 or > 120 mm Hg
Once the 24-h systo-diastolic blood pressure tracing has been obtained, the data should be interpreted using the appropriate pediatric nomograms (Tables 6, 7, 8 and 9) and bearing in mind the technical aspects reported above.
In pediatric age ABPM should not be used “routinely”. This test, can be extreme usefulness if used by skilled operators and if justified by specific questions (suspicion of white coat hypertension or masked hypertension, need for monitoring the effectiveness of a therapy, evaluation of the presence or absence of nocturnal dipping). The use of ABPM is particularly helpful in children aged more than 10 years. In younger children, who often do not tolerate the examination, ABPM should be used in targeted cases and bearing in mind that, in this age group, office blood pressure values are lower than those found with ABPM, and that this phenomenon tends to attenuate over the years. A future goal regarding ABPM in children will be to obtain more reference data for different age ranges and different ethnicities. It is also important to perform studies that assess the association between ambulatory blood pressure values and organ damage, not only by considering mean values, but also by examining anomalies regarding pressure load and the absence of physiological nocturnal dipping. Finally, it would be extremely useful to carry out prospective studies that could verify if normalization of 24-h blood pressure values is or is not accompanied by a regression of pre-existing organ damage.
Hypertension and physical activity: about prevention, therapy and certifications
Physical activity, be it playful and recreational or structured in organized sports, represents a fundamental cornerstone in the prevention and treatment of hypertension in pediatric age. This consideration, even though shared by all pediatricians and supported by broad evidence, is generally taken for granted and only briefly mentioned in the recommendations of the scientific societies dedicated to this subject. On the contrary, in the present update we dedicate a section to physical activity that is adequate and moreover proportional to our conviction that it is a primary and irreplaceable instrument in the prevention and treatment of hypertension in view of the well-known effects physical activity has on the pathogenetic mechanisms of hypertension. Furthermore, we will shortly deal with the legal aspects of the certifications for sports practice and the (few) contraindications for physical activity to be taken into consideration in children and adolescents with hypertension.
Prevention of hypertension and its risk factors by physical activity
The prevention of primary hypertension in children and adolescents is based on an intervention strategy on modifiable risk factors. Among these, the ones with the greatest impact are: overweight, diet, salt intake, sedentary behavior, bad sleep quality and cigarette smoking (also passive). Physical exercise may exert a possible effect on: overweight, sodium balance and bad quality of sleep, thus acting indirectly on the metabolic mechanisms involved in the development and maintenance of pressure increase, such as deposition and distribution of the fat mass, insulin resistance, activation of the sympathetic nervous system, sodium homeostasis, renin-angiotensin system, regulation of vascular function.
Obesity is the main risk factor for hypertension in children and adolescents. A recent meta-analysis analyzed the effects of childhood obesity prevention programs on hypertension . The most effective interventions, excluding the ones aiming at children who were already overweight or obese, were shown to be those combining dietary interventions with physical activity. The mean reduction in blood pressure obtained after 6–12 months with the combination of the two strategies was 1.64 mmHg for systolic and 1.44 mmHg for diastolic blood pressure. When intervening solely on diet or physical activity the results were shown to be less successful. For that matter, even if apparently quite modest, a reduction of blood pressure of 2 mmHg reduces the risk of hypertension in adulthood by up to 10 % . Another meta-analysis examined nine randomized controlled trials in order to analyze the effect of physical exercise on blood pressure at rest in obese children . The results revealed that programs comprising three exercise sessions a week, each lasting more than 60 min, induced a reduction in systolic blood pressure between −0.58 and −0.82 mmHg. Only if the frequency of exercise sessions was higher than three times a week it was possible to observe a reduction in diastolic blood pressure as well.
On the average sodium intake in children and adolescents exceeds the recommended quantities . Physical activity practiced on a regular basis induces sodium loss through sweating, thus favoring the achievement and/or maintenance the equilibrium of the sodium balance . If the level of exercise is intensified, sweating and consequently sodium loss increases. The recommendation for practice of physical activity in children at the Centers for Disease Control and Prevention USA indicates at least 60 min daily of moderate or intense activity, with at least three sessions of vigorous activity a week . The many different personal and environmental factors influencing the amount of sweat produced make it difficult to quantify the relative impact of sodium loss by sweating due to physical activity on the overall effect of physical exercise on blood pressure.
Duration of sleep is inversely correlated to cardio-metabolic risk, obesity and levels of physical activity in children [94, 95]. Children that sleep more than 9 h a night present a more intense physical activity level and are leaner than children that sleep less. However, it is not known if it is the higher level of motor activity (duration and/or intensity) that causes an increase in duration of sleep or vice versa . Also the regularity of sleep duration during weekdays and the weekend is related to a higher level of physical activity . The amount of time spent watching TV or playing videogames is found to be associated with a shorter duration of sleep .
Physical activity in the treatment of children and adolescents with hypertension
The benefits of physical activity for the treatment of hypertension have been well documented for what regards hypertensive adults, both with and without obesity [98, 99]. On the contrary evidence is less strong in pediatric age, in which the majority of meta-analyses and systematic reviews focus on the effectiveness of physical activity on blood pressure values in obese children and adolescents, as obesity represents the most frequent cause of hypertension in this age range. The mechanisms by which physical activity may affect blood pressure in obese children and adolescents are not yet well known. It is hypothesized that physical exercise, i.e., physical activity performed in a structured manner according to precise criteria regarding type, duration, intensity and frequency, acts on various mechanisms involved in the onset of hypertension, determining a reduction in insulin resistance and beneficial adaptation of the cardiovascular system (reduction in sympathetic tone, reduction in arterial stiffness, reduction in endothelial dysfunction) . Furthermore, reduction in body mass index (BMI), due to the negative caloric balance achieved when physical activity is associated with a diet, can cause a reduction in blood pressure of 8–12 mmHg . Some observational studies demonstrated a significant relationship between active lifestyle, aerobic fitness and levels of blood pressure . Therefore, lifestyle changes by increasing physical activity and reducing sedentary behavior represent the first intervention strategy in pediatric hypertension (in combination with diet, reduction of stress factors, and avoidance of smoke and alcohol) in patients with high-normal blood pressure or with stage 1 hypertension ; at the same time, such interventions represent a complementary and irreplaceable therapy in those cases in which pharmacological treatment is needed. In order to achieve the highest probability of success, the whole family should participate in changing the dysfunctional behavior. For what concerns the type, intensity and duration of physical exercise to be advised in the treatment of pediatric hypertension, experimental studies have shown a greater efficacy of aerobic exercise (systolic blood pressure −1.39 mmHg; diastolic blood pressure −0.39 mmHg) compared to muscular strength training (systolic blood pressure −0.61 mmHg; diastolic blood pressure −0.51 mmHg) . The training programs based on three weekly sessions lasting more than 60 min each, were found to be more effective on systolic blood pressure, while programs with more than three sessions per week had a greater impact on diastolic blood pressure. Even though the effect on blood pressure values may seem quite modest, it has been hypothesized that the reduction of at little as 1 mmHg in childhood may have an impact on the blood pressure in adult age and on future cardiovascular events, in view of the long cumulative period of exposure . A meta-analysis of studies in adults has shown that a reduction of blood pressure by 2 mmHg can reduce cardiovascular event risk by 12 % . Therefore, on the basis of scientific evidence, it is recommended to practice physical activity for at least 5 days a week, lasting 30–60 min at moderate to vigorous intensity  (moderate physical activity: reaching 55–75 % of maximum heart rate; vigorous physical activity: reaching 65–85 % of maximum heart rate). The physical activity can be performed both as a non-organized activity and as a physical exercise or sport. In case a condition of elevated blood pressure is diagnosed in children that already participate in one or more physical activities, it may be necessary to increase the frequency and/or intensity. Aerobic activities are to be preferred (walking, running, cycling, swimming, rowing) over static forms of exercise. Moreover, considering the negative and independent effect of sedentary behavior on cardio-metabolic health, children and adolescents should be educated to monitor the time spent in sedentary activities (TV, videogames, computer), aiming at gradually reducing the time dedicated to these activities to less than 2 h a day . Significant effects of exercise have been shown after 3–6 months from the start of the training program , but this should continue in time in order to obtain a more lasting effect on blood pressure control. It is also recommended not to interrupt the physical exercise programs, as blood pressure returns to pre-training values within a few months after the cessation of the exercise.
Aspects related to the certification for physical activities and contraindications for sports activities in hypertensive children and adolescents
Sporting activities with mainly pressure-related cardiocirculatory involvement, characterized by increased-to-maximal heart rate, mean-to-increased peripheral resistances and a non-maximal cardiac output
Athletics: speed, jumps, leaps, heptathlon, decathlon
Weight lifting, Bodybuidling
Speed cycling, Mountain bike downhill, BMX
Motorcycling (Motocross, Enduro, Trial)
Skiing: slalom, giant slalom, super G, downhill, alpine, snowboard, carving, grass skiing.
In Italy, unlike what happens in the United States, in order to engage in any non-agonistic sports activity a medical certification is requested, that involves civil and penal responsibilities of the certifying doctor and that is regulated by specific decrees, in particular by the most recent changes described in the so-called Balduzzi decree . For obtaining this certification in healthy, or apparently healthy children, as defined in generic terms, blood pressure measurement and at least one electrocardiogram at rest should be performed (as explicitly specified in the wording on the certificate to be signed afterwards by the physician). In the case of children and adolescents suffering from hypertension, both primary and secondary, it is necessary to pay more attention, both considering the cardiovascular stress that this state may involve, and considering the importance of implementing the lifestyle changes, that should always represent the first, non-pharmacological, step that may be useful in maintaining blood pressure values within the normal range. In special cases (e.g., obese patient losing weight) it is possible to certify suitability for moderate non-agonistic sports, with a frequency of maximum 2–3 h a week in order to attain improvement in lifestyle without at the same time weighing negatively on the cardiovascular and osteoarticular apparatus. On the other hand, for participation in agonistic sports activities, children have to be referred to Sports Medicine Specialists, who are qualified to decide what examinations should be performed in order to obtain certification of suitability for the specific sport and who finally sign the certificate.
Simple carbohydrates, fructose, uric acid and hypertension
In this section we will deal with the relationship between blood pressure, simple carbohydrates (fructose in particular) and uric acid in pediatric age. As the metabolisms of these compounds are strongly interconnected, it is not easy to distinguish the specific role of each of them. Furthermore, they are also associated with parameters that characterize the metabolic syndrome, such as hypertriglyceridemia, low levels of HDL-cholesterol, hyperinsulinemia, type 2 diabetes mellitus, fatty liver, in addition to their role in the development and progression of renal disease.
For the sake of clarity each compound is taken into consideration separately.
This term comprehends both the monosaccharides glucose and fructose and the disaccharide sucrose, all used in the food industry, in homemade preparations or directly by the consumer and which are also the sugars naturally contained in honey, syrups, juices or fruit concentrates. One molecule of glucose bound to one of fructose by a glycosidic linkage form one molecule of sucrose, the common table sugar. In 2000 the dietary consumption of simple carbohydrates in the Unites States was found to amount to 72.6 kg/person/year and it has been calculated that about 40 % of this total was accounted for by sweetened beverages . This consumption, involving children to a large extent, introduces a considerable caloric amount and may be a decisive contributing factor to the current epidemics of overweight , considering the fact that calories originating from liquids do not tend to cause a sense of satiety, whereas those in solid foods normally do [117, 118]. In these cases we are talking about an additional caloric intake up to about 200–300 Kcal a day. The relationship between overweight and hypertension in pediatric age is well-known and has been widely discussed in our previous article . Furthermore it has been shown that sugar consumption is positively correlated with salt intake, both in adults and in children [120, 121], and this could represent an additional mechanism favoring elevated blood pressure values.
Fructose is the sugar that can be found in fruit, but in the present-day diet, the amount of fructose actually deriving from fruit is quite modest. An important proportion of the intake of fructose derives from sucrose, while another major source of fructose is represented by high fructose corn syrup (HFCS). This is an industrially produced syrup derived from corn starch, introduced in the seventies, which contains 55-60 % of fructose and is obtained by isomerization of glucose. These syrups are frequently used in the food industry for the production of various prepackaged foods that do not necessarily have a sweet taste, like crackers or ketchup, but are actually mainly employed in the production of sweetened beverages. Finally, currently fructose is also being used in several sweeteners. A moderate fructose intake, especially when deriving from fruit consumption, is well tolerated. What does cause quite a lot of concern, even though not yet shared by the public opinion, is an excessive fructose load as the human body does not envisage any system to regulate its metabolism. Fructose can be internalized by all types of cells, but the mechanisms of intracellular transport of this carbohydrate are most efficient in the liver and kidneys, and so these two organs are mainly involved in its metabolism. Unlike what happens with glucose, the intracellular use of fructose does not depend on any control system that considers the energetic state of the cell. As a consequence, abundant amounts of fructose induce an uncontrolled cascade synthesis of fatty acids, whereas equivalent amounts of glucose would not cause such effects . Furthermore, when entering the cell fructose is phosphorylated by an ATP-dependent fructokinase. The presence of an excess amount of fructose causes an increased ATP consumption, that cannot be restored due to a relative phosphorus deficiency and in turn this leads to progressive degradation of the high-energy compounds to metabolized adenosine and finally uric acid . Moreover, it is suggested that large amounts of fructose induce an increased activity of the enzyme fructokinase, while fructose itself may also reduce renal secretion of urates . The final result of these interlinked effects is an increase in blood uric acid after excessive consumption of fructose. The consequences of high uric acid levels will be analyzed separately. Compared to glucose, fructose appears to cause a weaker sense of satiety due to its inability to increase insulin and leptin secretion and to inhibit ghrelin secretion, which are all compounds having a stimulating or inhibiting effect on the satiety center in the brain . Fructose is also believed to decrease basal metabolism . It increases reabsorption of salt and water in the intestine and in the kidneys and it has been shown that a diet at high contents of both fructose and sodium together is more easily associated with the development of hypertension than a solely high-fructose diet . Fructose has also been reported to induce oxidative stress and to provoke vasoconstriction by inhibiting endothelial nitric oxide synthase . In experimental animals also a negative effect of fructose on the kidneys has been revealed, inducing the development of renal hypertrophy, glomerular hypertension, cortical vasoconstriction and preglomerular arteriolopathy. If high fructose intake is maintained for a long time, the renal damage, which may be modest in the initial phases, will tend to become chronic and may cause systemic hypertension in the long run . Although a marked increase in the risk of gout has been demonstrated in subjects with a particularly high-fructose diet, this event is very rare in young individuals. In spite of this, the intake of sugar-sweetened drinks is associated with an increased risk of hyperuricemia  and these observations have been reconfirmed in a vast cohort of children and adolescents , in whom an increased intake of these kind of beverages corresponded with a significant increase both in uric acid levels and in blood pressure even after correction for potential confounding factors such as BMI. These data suggest other mechanisms, besides through obesity, by which sugar-sweetened drinks may play a role in the development of hypertension in the adolescents. Intervention studies have shown that reduction of carbohydrate consumption can slow the development of the metabolic syndrome more effectively than the typical diets that mainly reduce intake of fat. A study in California has demonstrated that banning soft drinks in schools caused a reduction in their daily consumption associated with a significant reduction of obesity in children between 6 and 11 years of age .
Uric acid is produced during the breakdown of the purine bases adenine and guanine. A diet containing food at high concentrations of these compounds can bring about an increase in uric acid level in the blood, especially in the presence of minor metabolic dysfunctions in specific subjects. However, one should not forget the role that excessive fructose intake can have in increasing uric acid (see previous paragraph). Uric acid can exert negative effects even at concentrations that are lower than the ones provoking precipitation of urate crystals in the joints. In children and adolescents it is advised to attentively examine also uric acid levels that are at the upper limit of the normal range. The relationship between uric acid levels and blood pressure values was hypothesized many years ago, but lately research in this field has become quite strong, producing numerous data deriving from both animal and human studies, some with interesting results in pediatric age . In experimental moderately hyperuricemic rats it has been observed that uric acid reduces the production of nitric oxide both at endothelial and renal level with a consequent vasoconstriction in these particular areas . At vascular level uric acid stimulates smooth muscle cell proliferation, whereas it inhibits production of new endothelial cells. These effects, typically involved in what is generally called endothelial dysfunction, seem to cause blood pressure elevations and reductions in blood flow to the skeletal muscle, that, consequently, needs more insulin for the uptake and disposal of excess glucose, resulting in a clear-cut effect of insulin resistance. Furthermore, such vascular alterations induce arteriolar hyalinosis, described mainly at the level of the afferent arterioles of mildly hyperuricemic rats, in which a further activation of the renin-angiotensin-aldosterone system and the onset of sodium sensitivity have been observed, both factors that clearly contribute to the development of hypertension. The comprehensive data deriving from experimental studies performed in both animals and humans suggest the existence of two steps in the pathogenetic mechanisms that link uric acid to the development of hypertension . Initially uric acid activates the renin-angiotensin-aldosterone system and suppresses nitric oxide, causing a functional increase in the vascular resistances at systemic level. This is followed by a second phase characterized by the development of arteriosclerosis of the afferent glomerular arterioles and the onset of sodium sensitivity, which are both structural changes and thus hardly reversible. Uric acid presents antioxidant properties in the extracellular space, suggesting that it may play a protective role against some disease conditions. Nevertheless, many studies have shown that once uric acid enters the cells, it starts to assume a pro-inflammatory role. Intracellular uptake of uric acid is mediated by the transporter URAT1. At smooth muscle cell level, the entry of uric acid causes activation and production of growth factors and of MCP-1 , which is a chemokine involved in the formation of inflammatory infiltrates and implied in the development of insulin resistance, because of its additional capacity to reduce glucose uptake at the myocyte level. Internalization of uric acid in adipocytes through URAT1 has been found on the one hand to induce MCP-1 production and on the other hand to reduce production of insulin sensitizers such as PPARγ and adiponectin , thus contributing in an even more structured manner to the development of insulin resistance. In the kidneys, hyperuricemia has particularly clear effects in animals with pre-existing renal disease as it can aggravate both glomerulosclerosis and tubulointerstitial damage . Instead, lowering uric acid by drug treatment has been demonstrated to attenuate the progression of renal disease and hypertension . Entry of uric acid in human proximal renal tubule cells causes apoptosis due to a mechanism that is mediated by the activation of pro-oxidant systems  and this may explain, at least partly, the results of clinical studies describing how even moderately increased uric acid levels are associated both with the onset and with the progression of chronic renal disease in different clinical settings . Non-alcoholic fatty liver disease (NAFLD) is the result of abnormal fat accumulation in the liver and has recently been found to be strongly related to the presence of insulin resistance, metabolic syndrome and increases uric acid levels. Indeed, uric acid contributes both to lipoprotein oxidation and to inflammation, two important factors in the development and progression of NAFLD. The association between NAFLD and unfavorable cardiovascular risk profile is increasingly supported by scientific evidence also in the pediatric population . Preliminary data in animal models suggest that hypouricemic therapy may improve the severity of steatosis . In humans the increase in uric acid has been demonstrated to be an independent predictor of obesity, hyperinsulinemia, diabetes, systemic hypertension, cardiovascular and renal diseases . In particular, a recent meta-analysis shows that the relationship between uric acid levels and the development of hypertension is dose-dependent . Some recent publications also concerned subjects in the pediatric age range. Various authors described the contemporaneous presence of high uric acid levels and metabolic alterations . Ford reported that an association between uric acid and components of the metabolic syndrome, particular visceral obesity, is already present in children and adolescents. In obese children also a significant correlation between uric acid plasma levels, blood pressure and HOMA index has been reported, suggesting a possible role of uric acid in the pathogenesis of pediatric essential hypertension mediated by the presence of insulin resistance . A close relationship between uric acid levels and components of the metabolic syndrome has also been shown in a population of Japanese adolescents . Feig was the first author to describe an association between uricemia and the presence of hypertension in a cohort of children and adolescents . It is interesting to emphasize that elevated urate levels were found in subjects with primary hypertension. Jones  confirmed the relationship between uric acid and blood pressure levels in a cohort of 104 children with primary hypertension, undergoing 24 h ambulatory blood pressure monitoring. This relationship persisted even after correction for age, gender, race and BMI. Afterwards other authors strengthened the evidence of this type of association. Particularly worthy of note is a study derived from the US registers (NHANES), demonstrating in over 6000 adolescents that those who had hypertension showed higher uric acid levels . Recently, in a cohort of children at relatively high cardiovascular risk, a significant correlation has been described between increasing levels of uric acid and the grade/category of essential hypertension (transient hypertension, prehypertension and sustained hypertension), which persisted after correction for possible confounders, including HOMA-index . It has also been suggested that minor increases in uricemia in children may predict the onset of hypertension in adulthood . At this moment the role of uric acid as risk factor for the development of cardiovascular and renal damage in very young children is being studied. There are some preliminary reports indicating a higher prevalence of carotid atherosclerosis in adolescents with increased uric acid levels . The relationship between uric acid and renal tubular damage has recently been demonstrated also in a population of hypertensive adolescents with normal renal function, in whom a slight increase in uric acid correlated with an increased urinary excretion of early markers of renal injury such as NGAL and KIM-1 . Two randomized studies in hypertensive and prehypertensive adolescents have revealed a reduction of systolic and diastolic blood pressure values coinciding with the administration of uric acid lowering drugs, suggesting a direct causal relationship between urate and hypertension in these subjects [155, 156]. Further studies are needed in order to understand if uric acid lowering pharmacological treatment should be taken into consideration for hypertensive children. Recent findings support the view that maintaining relatively low uric acid values over time could be more effective at preventing the onset of hypertension than lowering uric acid, to reduce blood pressure levels once hypertension is established . However, further studies are needed in order to understand if uric acid is really implicated in the pathogenesis of essential hypertension in children and adolescents.
Foods to pay attention to in case of elevated serum levels of uric acid
Foods at very high purine content (avoid)
Anchovies, brains, game, gravy, herring, kidney, liver, sardines, shellfish, sweetbread.
Foods at high purine content (limit)
Asparagus, beef stock, cauliflower, eel, legumes (beans, lentils, peas), meat (beef, lamb, pork, veal), mushrooms, oatmeal, wheat bran, wheat germ.
No funding declared.
SM, GM, GS have planned, coordinated and critically revised the draft. EM, PS, FS drafted the section “Hypertension in newborns and unweaned babies”. GS, CC, PS drafted the section “Ambulatory blood pressure monitoring in pediatric hypertension: how and when to use it”. BP, GU, MC, VG drafted the section “Hypertension and physical activity: about prevention, therapy and certifications”. AMA, VF, GM, GS drafted the section “Simple carbohydrates, fructose, uric acid and hypertension”. MS, MMC, SP, VR have critically revised some parts of the draft. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Task Force on Blood Pressure Control in Children. Report of the Second Blood Pressure Control in Children −1987. Pediatrics. 1987;79:1–25.Google Scholar
- Kent AL, Kecskes Z, Shadbolt B, Falk MC. Blood pressure in the first year of life in healthy infants born at term. Pediatr Nephrol. 2007;22:1743–9.PubMedView ArticleGoogle Scholar
- Cantinotti M, Giordano R, Scalese M, Molinaro S, Murzi B, Assanta N, et al. Strengths and limitations of current pediatric blood pressure nomograms: a global overview with a special emphasis on regional differences in neonates and infants. Hypertens Res. 2015;38:577–87.Google Scholar
- Zubrow AB, Hulman S, Kushner H, Falkner B. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. J Perinatol. 1995;15:470–9.PubMedGoogle Scholar
- Kent AL, Meskell S, Falk MC, Shadbolt B. Normative blood pressure data in nonventilated premature neonates from 28–36 weeks gestation. Pediatr Nephrol. 2009;24:141–6.PubMedView ArticleGoogle Scholar
- Flynn JT. Neonatal hypertension: diagnosis and management. Pediatr Nephrol. 2000;14:332–41.PubMedView ArticleGoogle Scholar
- Pejovic B, Peco-Antic A, Marinkovic-Eric J. Blood pressure in noncritically ill preterm and full-term neonates. Pediatr Nephrol. 2007;22:249–57.PubMedView ArticleGoogle Scholar
- Lurbe E, Garcia-Vicent C, Torro I, Fayos JL, Aguilar F, de Llano JM, et al. First-year blood pressure increase steepest in low birthweight newborns. J Hypertens. 2007;25:81–6.PubMedView ArticleGoogle Scholar
- Sadoh WE, Ibhanesehbor SE, Monguno AM, Gubler DJ. Predictors of newborn systolic blood pressure. West African J Med. 2010;29:86–90.Google Scholar
- Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management and outcome. Pediatr Nephrol. 2012;27:159–60.View ArticleGoogle Scholar
- Dannevig I, Dale H, Liestol K, Lindemann R. Blood pressure in the neonate: Three non-invasive oscillometric pressure monitors compared with invasively measure blood pressure. Acta Paediatr. 2005;94:191–6.PubMedView ArticleGoogle Scholar
- Devinck A, Keukelier H, De Savoye I, Desmet L, Smets K. Neonatal blood pressure monitoring: visual assessment is un unreliable method for selecting cuff sizes. Acta Paediatr. 2013;102:961–4.PubMedView ArticleGoogle Scholar
- Neal WA, Reynolds JW, Jarvis CW, Williams HJ. Umbilical artery catheterization: demonstration of arterial thrombosis by aortography. Pediatrics. 1972;50:6–13.PubMedGoogle Scholar
- Seibert JJ, Taylor BJ, Williamson SL, Williams BJ, Szabo JS, Corbitt SL. Sonographic detection of neonatal umbilical artery thrombosis: clinical correlation. Am J Roentgenol. 1987;148:965–8.View ArticleGoogle Scholar
- Ford KT, Teplick SK, Clark RE. Renal artery embolism causing neonatal hypertension. Radiology. 1974;113:169–70.PubMedView ArticleGoogle Scholar
- Bauer SB, Feldman SM, Gellis SS, Retik AB. Neonatal hypertension: a complication of umbilical-artery catheterization. N Engl J Med. 1975;293:1032–3.PubMedView ArticleGoogle Scholar
- Plumer LB, Kaplan GW, Mendoza SA. Hypertension in infants: a complication of umbilical arterial catheterization. J Pediatr. 1976;89:802–5.PubMedView ArticleGoogle Scholar
- Seliem WA, Falk MC, Shadbolt B, Kent AL. Antenatal and postnatal risk factors for neonatal hypertension and infant follow-up. Pediatr Nephrol. 2007;22:2081–7.PubMedView ArticleGoogle Scholar
- Abman SH, Warady BA, Lum GM, Koops BL. Systemic hypertension in infants with bronchopulmonary dysplasia. J Pediatr. 1984;104:929–31.View ArticleGoogle Scholar
- Sahu R, Pannu H, Yu R, Shete S, Bricker JT, Gupta-Malhotra M. Systemic Hypertension Requiring Treatment in the Neonatal Intensive Care Unit. J Pediatr. 2013;163:84–8.PubMedPubMed CentralView ArticleGoogle Scholar
- Alagappan A, Malloy MH. Systemic hypertension in very low-birth weight infants with bronchopulmonary dysplasia: Incidence and risk factors. Am J Perinatol. 1998;15:3–8.PubMedView ArticleGoogle Scholar
- Abman SH. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal. 2002;87:F15–18.View ArticleGoogle Scholar
- Singh HP, Hurley RM, Myers TF. Neonatal hypertension. Incidence and risk factors. Am J Hypertens. 1992;5:51–5.PubMedGoogle Scholar
- Farmakis SG, Khanna G. Extracardiac applications of MR blood pool contrast agent in children. Pediatr Radiol. 2014;44:1598–609.PubMedView ArticleGoogle Scholar
- Favilli S, Capuzzo L. Pollini I Usefulness of Doppler ultrasound in the diagnosis of renal artery stenosis in hypertensive children. Two case reports and review of the literature. Ital Heart J Suppl. 2004;5:492–6.PubMedGoogle Scholar
- Lanzarini VV, Furusawa EA, Sadeck L, Leone CR, Vaz FA, Koch VH. Neonatal arterial hypertension in nephrourological malformations in a tertiary care Hospital. J Hum Hypertens. 2006;20:679–83.PubMedView ArticleGoogle Scholar
- Lindle KA, Dinh K, Moffet BS, Kyle WB, Montgomery NM, Denfield SD, et al. Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease. Pediatr Cardiol. 2014;35:499–506.PubMedView ArticleGoogle Scholar
- Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr. 1988;112:805–10.PubMedView ArticleGoogle Scholar
- Filippi L, Cavallaro G, Bagnoli P, Dal Monte M, Fiorini P, Donzelli G, et al. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr. 2013;163(6):1570–7.PubMedView ArticleGoogle Scholar
- Blowey DL, Duda PJ, Stokes P, Hall M. Incidence and treatment of hypertension in the neonatal intensive care unit. J Am Soc Hypertens. 2011;6:478–83.View ArticleGoogle Scholar
- Lorell BH. Transition from hypertrophy to failure. Circulation. 1997;96:3824–7.PubMedGoogle Scholar
- Samuelsson O, Wilhelmsen L, Elmfeldt D, Pennert K, Wedel H, Wickstrand J, et al. Predictors of cardiovascular morbidity in treated hypertension: results from the primary preventive trial in Goteborg, Sweden. J Hypertens. 1985;3:167–76.PubMedView ArticleGoogle Scholar
- Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561–6.PubMedView ArticleGoogle Scholar
- Pieruzzi F, Antolini L, Salerno FR, Giussani M, Brambilla P, Galbiati S, et al. The role of blood pressure, body weight and fat distribution on left ventricular mass, diastolic function and cardiac geometry in children. J Hypertens. 2015;33:1182–92.PubMedView ArticleGoogle Scholar
- Kupferman JC, Paterno K, Mahgerefteh J, Pagala M, Golden M, Lytrivi ID, et al. Improvement of left ventricular mass with antihypertensive therapy in children with hypertension. Pediatr Nephrol. 2010;25:1513–8.PubMedView ArticleGoogle Scholar
- Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–8.PubMedView ArticleGoogle Scholar
- Joyce JJ, Dickson PI, Qi N, Noble JE, Raj JU, Baylen BJ. Normal Right and Left Ventricular Mass Development During Early Infancy. Am J Cardiol. 2004;93:797–801.PubMedView ArticleGoogle Scholar
- Peterson AL, Frommelt PC, Mussatto K. Presentation and Echocardiographic Markers of Neonatal Hypertensive Cardiomyopathy. Pediatrics. 2006;118:e782–5.PubMedView ArticleGoogle Scholar
- Salice P, Mannarino S, Fesslova V. Modification of LV mass in hypertensive newborns and infants. G Ital Cardiol. 2001;2(Suppl4):17S.Google Scholar
- Levent E, Goksen D, Ozyurek AR, et al. Stiffness of the abdominal aorta in obese children. J Pediatr Endocrinol Metab. 2002;15:405–9.PubMedView ArticleGoogle Scholar
- Iannuzzi A, Licenziati MR, Acampora C, et al. Preclinical changes in the mechanical properties of abdominal aorta in obese children. Metabolism. 2004;53:1243–6.PubMedView ArticleGoogle Scholar
- Koudsi A, Oldroyd J, McElduff P, Banerjee M, Vyas A, Cruickshank JK. Maternal and neonatal influences on, and reproducibility of neonatal aortic pulse wave velocity. Hypertension. 2007;49:225–31.PubMedView ArticleGoogle Scholar
- Cheung Y-F. Arterial stiffness in the young:assessment, determinants, and implications. Korean. Circ J. 2010;40:153–62.Google Scholar
- Stergiotou I, Crispi F, Valenzuela-Alcaraz B, Cruz-Lemini M, Bijnens B, Gratacos E. Aortic and carotid intima-media thickness in term small-for-gestational-age newborns and relationship with prenatal signs of severity Ultrasound. Obstet Gynecol. 2014;43(6):625–31.Google Scholar
- Ingelfinger JR, Nuyt AM. Impact of Fetal Programming, Birth Weight, and Feeding on Later Hypertension. J Clin Hypertens. 2012;14:365–71.View ArticleGoogle Scholar
- Ingelfinger JR, Woods LL. Perinatal programming, renal development, and adult renal function. Am J Hypertens. 2002;15:46S–9S.PubMedView ArticleGoogle Scholar
- Barker DJ, Gelow J, Thornburg K, Osmond C, Kajantie E, Eriksson JG. The early origins of chronic heart failure: impaired placental growth and initiation of insulin resistance in childhood. Eur J Heart Fail. 2010;12:819–25.PubMedView ArticleGoogle Scholar
- Genovesi S, Brambilla P, Giussani M, Galbiati S, Mastriani S, Pieruzzi F, et al. L. Insulin resistance, prehypertension, hypertension and blood pressure values in paediatric age. J Hypertens. 2012;30:327–35.PubMedView ArticleGoogle Scholar
- Dalziel SR, Parag V, Rodgers A, Harding JE. Cardiovascular risk factors at age 30 following pre-term birth. Int J Epidemiol. 2007;36:907–15.PubMedView ArticleGoogle Scholar
- Kistner A, Celsi G, Vanpee M, Jacobson SH. Increased blood pressure but normal renal function in adult women born preterm. Pediatr Nephrol. 2000;15:215–20.PubMedView ArticleGoogle Scholar
- Doyle LW, Faber B, Callanan C, Morley R. Blood pressure in late adolescence and very low birth weight. Pediatrics. 2003;111:252–7.PubMedView ArticleGoogle Scholar
- Mathai S, Derraik JG, Cutfield WS, Dalziel SR, Harding JE, Biggs JB, et al. Blood pressure abnormalities in adults born moderately preterm and their children. Int J Cardiol. 2015;181:152–4.PubMedView ArticleGoogle Scholar
- Singhal A, Kattenhorn M, Cole TJ, Deanfield J, Lucas A. Preterm birth, vascular function, and risk factors for atherosclerosis. Lancet. 2001;358:1159–60.PubMedView ArticleGoogle Scholar
- He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2013;30(4):CD004937.Google Scholar
- Tabara Y, Takahashi Y, Kumagai K, Seton K, Kawaguchi T, Takahashi M, et al. Descriptive epidemiology of spot urine sodium-to-potassium ratio clarified close relationship with blood pressure level: the Nagahama study. J Hypertens. 2015;33:2407–13.PubMedView ArticleGoogle Scholar
- Urbina E, Alpert B, Flynn J, Hayman L, Harshfield GA, Jacobson M, et al. Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young and the Council for High Blood Pressure Research. Hypertension. 2008;52:433–51.PubMedView ArticleGoogle Scholar
- Wühl E, Witte K, Soergel M, Mehls O. Schaefer F; German Working Group on Pediatric Hypertension. Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions [published correction appears in J Hypertens. 2003;21:2205–2206]. J Hypertens. 2002;20:1995–2007.PubMedView ArticleGoogle Scholar
- National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics. 2004;114:555–76.View ArticleGoogle Scholar
- Koshy S, Macarthur C, Luthra S, Gajaria M, Geary D. Ambulatory blood pressure monitoring: mean blood pressure and blood pressure load. Pediatr Nephrol. 2005;20:1484–6.PubMedView ArticleGoogle Scholar
- White WB, Dey HM, Schulman P. Assessment of the daily blood pressure load as a determinant of cardiac function in patients with mild-to-moderate hypertension. Am Heart J. 1989;118:782–95.PubMedView ArticleGoogle Scholar
- Flynn JT, Daniels SR, Hayman LL, Maahs DM, McCrindle BW, Mitsnefes M, et al. American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension. 2014;63:1116–35.PubMedPubMed CentralView ArticleGoogle Scholar
- Juonala M, Magnussen CG, Venn A, Dwyer T, Burns TL, Davis PH, et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the international Childhood Cardiovascular Cohort (i3C) Consortium. Circulation. 2010;122:2514–20.PubMedView ArticleGoogle Scholar
- Koivistoinen T, Hutri-Kähönen N, Juonala M, Aatola H, Kööbi T, Lehtimäki T, et al. Metabolic syndrome in childhood and increased arterial stiffness in adulthood: the Cardiovascular Risk in Young Finns Study. Ann Med. 2011;43:312–9.PubMedView ArticleGoogle Scholar
- Li X, Li S, Ulusoy E, Chen W, Srinivasan SR, Berenson GS. Childhood adiposity as a predictor of cardiac mass in adulthood: the Bogalusa Heart Study. Circulation. 2004;110:3488–92.PubMedView ArticleGoogle Scholar
- Sorof JM, Cardwell G, Franco K, Portman RJ. Ambulatory blood pressure and left ventricular mass index in hypertensive children. Hypertension. 2002;39:903–8.PubMedView ArticleGoogle Scholar
- McNiece KL, Gupta-Malhotra M, Samuels J, Bell C, Garcia K, Poffenbarger T, et al. Left ventricular hypertrophy in hypertensive adolescents: analysis of risk by 2004 National High Blood Pressure Education Program Working Group staging criteria. Hypertension. 2007;50:392–5.PubMedPubMed CentralView ArticleGoogle Scholar
- Stergiou GS, Giovas PP, Kollias A, Rarra VC, Papagiannis J, Georgakopoulos D, et al. Relationship of home blood pressure with target-organ damage in children and adolescents. Hypertens Res. 2011;34:640–4.PubMedView ArticleGoogle Scholar
- Lengyel S, Katona E, Zatik J, Molnár C, Paragh G, Fülesdi B, et al. The impact of serum homocysteine on intima-media thickness in normotensive, white-coat and sustained hypertensive adolescents. Blood Press. 2012;21:39–44.PubMedView ArticleGoogle Scholar
- Stabouli S, Kotsis V, Papamichael C, Constantopoulos A, Zakopoulos N. Adolescent obesity is associated with high ambulatory blood pressure and increased carotid intimal-medial thickness. J Pediatr. 2005;147:651–6.PubMedView ArticleGoogle Scholar
- Litwin M, Niemirska A, Sladowska J, Antoniewicz J, Daszkowska J, Wierzbicka A, et al. Left ventricular hypertrophy and arterial wall thickening in children with essential hypertension. pressure with target-organ damage in children and adolescents. Pediatr Nephrol. 2006;21:811–9.PubMedView ArticleGoogle Scholar
- Mitsnefes MM, Kimball TR, Witt SA, Glascock BJ, Khoury PR, Daniels SR. Abnormal carotid artery structure and function in children and adolescents with successful renal transplantation. Circulation. 2004;110:97–101.PubMedView ArticleGoogle Scholar
- Aggoun Y, Farpour-Lambert NJ, Marchand LM, Golay E, Maggio ABR, Beghetti M. Impaired endothelial and smooth muscle functions and arterial stiffness appear before puberty in obese children and are associated with elevated ambulatory blood pressure. Eur Heart J. 2008;29:792–9.PubMedView ArticleGoogle Scholar
- Ettinger LM, Freeman K, DiMartino-Nardi JR, Flynn JT. Microalbuminuria and abnormal ambulatory blood pressure in adolescents with type 2 diabetes mellitus. J Pediatr. 2005;147:67–73.PubMedView ArticleGoogle Scholar
- Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002;347:797–805.PubMedView ArticleGoogle Scholar
- Samuels J, Ng D, Flynn JT, Mitsnefes M, Poffenbarger T, Warady BA, et al. Chronic Kidney Disease in Children Study Group. Ambulatory blood pressure patterns in children with chronic kidney disease. Hypertension. 2012;60:43–50.PubMedPubMed CentralView ArticleGoogle Scholar
- McGlothan KR, Wyatt RJ, Ault BH, Hastings MC, Rogers T, Di Sessa T, et al. Predominance of nocturnal hypertension in pediatric renal allograft recipients. Pediatr Transplant. 2006;10:558–64.PubMedView ArticleGoogle Scholar
- Lande MB, Meagher CC, Fisher SG, Belani P, Wang H, Rashid M. Left ventricular mass index in children with white coat hypertension. J Pediatr. 2008;153:50–4.PubMedPubMed CentralView ArticleGoogle Scholar
- Páll D, Juhász M, Lengyel S, Molnár C, Paragh G, Fülesdi B, et al. Assessment of target-organ damage in adolescent white-coat and sustained hypertensives. J Hypertens. 2010;28:2139–44.PubMedView ArticleGoogle Scholar
- Kavey RE, Kveselis DA, Atallah N, Smith FC. White coat hypertension in childhood: evidence for end-organ effect. J Pediatr. 2007;150:491–7.PubMedView ArticleGoogle Scholar
- Litwin M, Niemirska A, Ruzicka M, Feber J. White coat hypertension in children: not rare and not benign? J Am Soc Hypertens. 2009;3:416–23.PubMedView ArticleGoogle Scholar
- Sorof JM, Poffenbarger T, Franco K, Portman R. Evaluation of whitecoat hypertension in children: Importance of the definitions of normal ambulatory blood pressure and the severity of casual hypertension. Am J Hypertens. 2001;14:855–60.PubMedView ArticleGoogle Scholar
- Lurbe E, Torro I, Alvarez V, Nawrot T, Paya R, Redon J, Staessen JA. Prevalence, persistence, and clinical significance of masked hypertension. Hypertension. 2005;45:493–8.PubMedView ArticleGoogle Scholar
- Stabouli S, Kotsis V, Toumanidis S, Papamichael C, Constantopoulos A, Zakopoulos N. White-coat and masked hypertension in children: association with target-organ damage. Pediatr Nephrol. 2005;20:1151–5.PubMedView ArticleGoogle Scholar
- Salice P, Ardissino G, Barbier P, Bacà L, Vecchi DL, Ghiglia S, et al. A Differences between office and ambulatory blood pressures in children and adolescents attending a hospital hypertension clinic. J Hypertens. 2013;31:2165–75.PubMedView ArticleGoogle Scholar
- Flynn JT. Differentiation between primary and secondary hypertension in children using ambulatory blood pressure monitoring. Pediatrics. 2002;110:89–93.PubMedView ArticleGoogle Scholar
- Flynn JT, Alderman MH. Characteristics of children with primary hypertension seen at a referral center. Pediatr Nephrol. 2005;20:961–6.PubMedView ArticleGoogle Scholar
- Sorof JM, Turner J, Franco K, Portman RJ. Characteristics of hypertensive children identified by primary care referral compared with school-based screening. J Pediatr. 2004;144:485–9.PubMedView ArticleGoogle Scholar
- Cai L, Wu Y, Wilson RF, Segal JB, Kim MT, Wang Y. Effect of childhood obesity prevention programs on blood pressure. A systematic review and meta-analysis. Circulation. 2014;129:1832–9.PubMedPubMed CentralView ArticleGoogle Scholar
- Ingelfinger JR. Pediatric antecedents of adult cardiovascular disease: awareness and intervention. N Engl J Med. 2004;350:2123–6.PubMedView ArticleGoogle Scholar
- Garcia-Hermoso A, Saavedra JM, Escalante Y. Effect of exercise on resting blood pressure in obese children: a meta-analysis of randomized controlled trials. Obesity Rev. 2013;14:919–28.View ArticleGoogle Scholar
- World Heath Organization. Guideline: Sodium intake for adults and children. Geneva, 2012. http://www.ncbi.nlm.nih.gov/books/NBK133297/
- Meyer F, Bar-Or O, MacDougall D, Heigenhauser GJ. Sweat electrolyte loss during exercise in the heat: effects of gender and maturation. Med Sci Sports Exerc. 1992;24:776–81.PubMedView ArticleGoogle Scholar
- US Department of Health and Human Services. 2008 physical activity guidelines for Americans. 2008. http://www.health.gov/PAGuidelines.
- Iglayreger HB, Peterson MD, Liu D, Parker CA, Woolford SJ, Sallinen Gafka BJ, et al. Sleep duration predicts cardiometabolic risk in obese adolescents. J Pediatr. 2014;164:1085–1090.e1.PubMedPubMed CentralView ArticleGoogle Scholar
- Archbold KH, Vasquez MM, Goodwin JL, Quan SF. Effects of sleep patterns and obesity on increases in blood pressure in a 5-year period: report from the Tucson Children’s Assessment of Sleep Apnea Study. J Pediatr. 2012;161:26–30.PubMedPubMed CentralView ArticleGoogle Scholar
- Stone MR, Stevens D, Faulkner GE. Maintaining recommended sleep throughout the week is associated with increased physical activity in children. Prev Med. 2013;56:112–7.PubMedView ArticleGoogle Scholar
- Magee C, Caputi P, Iverson D. Lack of sleep could increase obesity in children and too much television could be partly to blame. Acta Paediatr. 2014;103:e27–31.PubMedView ArticleGoogle Scholar
- Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493–503.PubMedView ArticleGoogle Scholar
- Semlitsch T, Jeitler K, Hemkens LG, Horvath K, Nagele E, Schuermann C, et al. A Increasing physical activity for the treatment of hypertension: a systematic review and meta-analysis. Sports Med. 2013;43:1009–23.PubMedView ArticleGoogle Scholar
- Torrance B, McGuire KA, Lewanczuk R, McGavock J. Overweight, physical activity and high blood pressure in children: a review of the literature. Vasc Health Risk Manag. 2007;3:139–49.PubMedPubMed CentralGoogle Scholar
- Flynn JT. Management of hypertension in children and adolescents in Clinic Pediatric Nephrology. In: Kanwal K, Sudesh Paul M, William H, editors. Informa Healthcare UK Ltd. Secondth ed. 2007.Google Scholar
- Janssen I, Leblanc AG. Systematic review of the health benefits of physical activity and fitness in school-aged children and youth. Int J Behav Nutr Phys Act. 2010;7:40.PubMedPubMed CentralView ArticleGoogle Scholar
- Puri M, Flynn JT. Management of Hypertension in Children and Adolescents With the Metabolic Syndrome. J Cardiometab Syndr. 2006;1:259–68.PubMedView ArticleGoogle Scholar
- Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. Circulation. 2008;117:3171–80.PubMedPubMed CentralView ArticleGoogle Scholar
- Verdecchia P, Gentile G, Angeli F, Mazzotta G, Mancia G, Reboldi G. Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens. 2010;28:1356–65.PubMedView ArticleGoogle Scholar
- Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics. 2011;128 Suppl 5:S213–56.PubMed CentralGoogle Scholar
- McCambridge TM, Benjamin HJ, Brenner JS, et al. Council on Sports Medicine and Fitness. Athletic participation by children and adolescents who have systemic hypertension. Pediatrics. 2010;125(6):1287–94.PubMedView ArticleGoogle Scholar
- Alpert BS. Exercise as a therapy to control hypertension in children. Int J Sports Med. 2000;21 suppl 2:S94–6. discussion S97.PubMedView ArticleGoogle Scholar
- Pate RR, Matthews C, Alpert BS, Strong WB, DuRant RH. Systolic blood pressure response to exercise in black and white preadolescent and early adolescent boys. Arch Pediatr Adolesc Med. 1994;148:1027–31.PubMedView ArticleGoogle Scholar
- MacDougall JD, Tuxen D, Sale DG, Moroz JR, Sutton JR. Arterial blood pressure response to heavy resistance exercise. J Appl Physiol. 1985;58:785–90.PubMedGoogle Scholar
- Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: Classification of Sports. J Am Coll Cardiol. 2005;45:1364–7.PubMedView ArticleGoogle Scholar
- American Academy of Pediatrics Council on Sports Medicine and Fitness. Policy statement – athletic participation by children and adolescents who have systemic hypertension. Pediatrics. 2010;125:1287–94.View ArticleGoogle Scholar
- Comitato Organizzativo Cardiologico per l’Idoneità allo Sport ANCE, ANMCO, FMSI, SIC, SIC SPORT. Protocolli cardiologici per il giudizio di idoneità allo sport agonistico 2009. Casa Editrice Scientifica Internazionale.Google Scholar
- Decreto-legge 13 settembre 2012, n. 158, e successive modifiche recante “Disposizioni urgenti per promuovere lo sviluppo del Paese mediante un più alto livello di tutela della salute”.Google Scholar
- Marriott BP, Olsho L, Hadden L, Connor P. Intake of added sugars and selected nutrients in the United States, National Health and Nutrition Examination Survey (NHANES) 2003–2006. Crit Rev Food Sci Nutr. 2010;50:228–58.PubMedView ArticleGoogle Scholar
- Malik VS, Schulze MB, Hu FB. Intake of sugar-sweetened beverages and weight gain: a systematic review. Am J Clin Nutr. 2006;84:274–88.PubMedPubMed CentralGoogle Scholar
- Sievenpiper JL, de Souza RJ, Mirrahimi A, Yu ME, Carleton AJ, Beyene J, et al. Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis. Ann Intern Med. 2012;156:291–304.PubMedView ArticleGoogle Scholar
- Bray GA. Energy and fructose from beverages sweetened with sugar or high-fructose corn syrup pose a health risk for some people. Adv Nutr. 2013;4:220–5.PubMedPubMed CentralView ArticleGoogle Scholar
- Spagnolo A, Giussani M, Ambruzzi AM, Bianchetti M, Maringhini S, Matteucci MC, et al. Focus on prevention, diagnosis and treatment of hypertension in children and adolescents. Ital J Pediatr. 2013;39:20.PubMedPubMed CentralView ArticleGoogle Scholar
- Mennella JA, Finkbeiner S, Lipchock SV, Hwang LD, Reed DR. Preferences for salty and sweet tastes are elevated and related to each other during childhood. PLoS One. 2014;9:e92201.PubMedPubMed CentralView ArticleGoogle Scholar
- Grimes CA, Riddell LJ, Campbell KJ, Nowson CA. Dietary salt intake, sugar-sweetened beverage consumption, and obesity risk. Pediatrics. 2013;131:14–21.PubMedView ArticleGoogle Scholar
- Cohen JC, Schall R. Reassessing the effects of simple carbohydrates on the serum triglyceride responses to fat meals. Am J Clin Nutr. 1988;48:1031–4.PubMedGoogle Scholar
- Stirpe F, Della Corte E, Bonetti E, Abbondanza A, Abbati A, De Stefano F. Fructose-induced hyperuricaemia. Lancet. 1970;2:1310–1.PubMedView ArticleGoogle Scholar
- Hu QH, Wang C, Li JM, Zhang DM, Kong LD. Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement. Am J Physiol Renal Physiol. 2009;297:F1080–1091.PubMedView ArticleGoogle Scholar
- Teff KL, Elliott SS, Tschöp M, Kieffer TJ, Rader D, Heiman M, et al. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab. 2004;89:2963–72.PubMedView ArticleGoogle Scholar
- Jürgens H, Haass W, Castañeda TR, Schürmann A, Koebnick C, Dombrowski F, et al. Consuming fructose-sweetened beverages increases body adiposity in mice. Obes Res. 2005;13:1146–56.PubMedView ArticleGoogle Scholar
- Singh AK, Amlal H, Haas PJ, Dringenberg U, Fussell S, Barone SL, et al. Fructose-induced hypertension: essential role of chloride and fructose absorbing transporters PAT1 and Glut5. Kidney Int. 2008;74:438–47.PubMedView ArticleGoogle Scholar
- Madero M, Perez-Pozo SE, Jalal D, Johnson RJ, Sánchez-Lozada LG. Dietary Fructose and Hypertension. Curr Hypertens Rep. 2011;13:29–35.PubMedView ArticleGoogle Scholar
- Sánchez-Lozada LG, Tapia E, Jiménez A, Bautista P, Cristóbal M, Nepomuceno T, et al. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol. 2007;292:F423–429.PubMedView ArticleGoogle Scholar
- Choi JW, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59:109–16.PubMedView ArticleGoogle Scholar
- Nguyen S, Choi HK, Lustig RH, Hsu CY. Sugar-sweetened beverages, serum uric acid, and blood pressure in adolescents. J Pediatr. 2009;154:807–13.PubMedPubMed CentralView ArticleGoogle Scholar
- Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62:3307–15.PubMedPubMed CentralView ArticleGoogle Scholar
- Feig DI, Madero M, Jalal DI, Sanchez-Lozada LG, Johnson RJ. Uric acid and the origins of hypertension. J Pediatr. 2013;162:896–902.PubMedView ArticleGoogle Scholar
- Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26:269–75.PubMedView ArticleGoogle Scholar
- Feig DI. Uric acid and hypertension. Semin Nephrol. 2011;31:441–6.PubMedView ArticleGoogle Scholar
- Kang DH, Han L, Ouyang X, Kahn AM, Kanellis J, Li P, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol. 2005;25:425–33.PubMedView ArticleGoogle Scholar
- Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60:1258–69.PubMedPubMed CentralView ArticleGoogle Scholar
- Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888–97.PubMedView ArticleGoogle Scholar
- Kosugi T, Nakayama T, Heinig M, Zhang L, Yuzawa Y, Sanchez-Lozada LG, et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol. 2009;297:F481–8.PubMedPubMed CentralView ArticleGoogle Scholar
- Verzola D, Ratto E, Villaggio B, Parodi EL, Pontremoli R, Garibotto G, Viazzi F. Uric acid promotes apoptosis in human proximal tubule cells by oxidative stress and the activation of NADPH oxidase NOX 4. PLoS One. 2014;9:e115210.PubMedPubMed CentralView ArticleGoogle Scholar
- Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013;28:2221–8.PubMedPubMed CentralView ArticleGoogle Scholar
- AlKhater SA. Paediatric non-alcoholic fatty liver disease: an overview. Obes Rev. 2015;16:393–405.PubMedView ArticleGoogle Scholar
- Xu CF, Yu CH, Xu L, Sa XY, Li YM. Hypouricemic therapy: a novel potential therapeutic option for nonalcoholic fatty liver disease. Hepatology. 2010;52:1865–6.PubMedView ArticleGoogle Scholar
- Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013;99:759–66.PubMedView ArticleGoogle Scholar
- Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, Li J. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014;9:e114259.PubMedPubMed CentralView ArticleGoogle Scholar
- Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation. 2007;115:2526–32.PubMedView ArticleGoogle Scholar
- Pacifico L, Cantisani V, Anania C, Bonaiuto E, Martino F, Pascone R, Chiesa C. Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. Eur J Endocrinol. 2009;160:45–52.PubMedView ArticleGoogle Scholar
- Hongo M, Hidaka H, Sakaguchi S, Nakanishi K, Ichikawa M, Hirota N, et al. Investigators of Study Project on Prevention of Metabolic Syndrome among Children, Adolescents, and Young Adults in Shinshu. Association between serum uric acid levels and cardiometabolic risk factors among Japanese junior high school students. Circ J. 2010;74:1570–7.PubMedView ArticleGoogle Scholar
- Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42:247–52.PubMedPubMed CentralView ArticleGoogle Scholar
- Jones DP, Richey PA, Alpert BS, Li R. Serum uric acid and ambulatory blood pressure in children with primary hypertension. Pediatr Res. 2008;64:556–61.PubMedPubMed CentralView ArticleGoogle Scholar
- Loeffler LF, Navas-Acien A, Brady TM, Miller 3rd ER, Fadrowski JJ. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999–2006. Hypertension. 2012;59:811–7.PubMedPubMed CentralView ArticleGoogle Scholar
- Viazzi F, Antolini L, Giussani M, Brambilla P, Galbiati S, Mastriani S, Stella A, Pontremoli R, Valsecchi MG, Genovesi S. Serum uric acid and blood pressure in children at cardiovascular risk. Pediatrics. 2013;132:e93–99.PubMedView ArticleGoogle Scholar
- Alper Jr AB, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension. 2005;45:34–8.PubMedView ArticleGoogle Scholar
- Tomczak J, Wasilewska A, Milewski R. Urine NGAL and KIM-1 in children and adolescents with hyperuricemia. Pediatr Nephrol. 2013;28:1863–9.PubMedPubMed CentralView ArticleGoogle Scholar
- Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924–32.PubMedPubMed CentralView ArticleGoogle Scholar
- Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60:1148–56.PubMedView ArticleGoogle Scholar
- Viazzi F, Rebora P, Giussani M, Orlando A, Stella A, Antolini L, Valsecchi MG, Pontremoli R, Genovesi S. Increased Serum Uric Acid Levels Blunt the Antihypertensive Efficacy of Lifestyle Modifications in Children at Cardiovascular Risk. Hypertension. 2016;67:934–40.PubMedView ArticleGoogle Scholar
- Zuccotti GV, Cassatella C, Morelli A, Cucugliato MC, Catinello G, del Balzo V, et al. Nutrient intake in Italian infants and toddlers from North and South Italy: the Nutrintake 636 study. Nutrients. 2014;6:3169–86.PubMedPubMed CentralView ArticleGoogle Scholar